Multiomics Advantage biomodal offers duet multiomics solutions that combine genetic and epigenetic data from a single low input sample, presenting a compelling value proposition for oncology, neurodegeneration, and aging research markets where integrated data can accelerate biomarker discovery and therapeutic insights.

Sequencing Compatibility Recent confirmation that biomodal's duet multiomics work with Element Biosciences AVITI 24 5D systems expands potential sales channels with a known high-throughput sequencing platform, enabling co-marketing opportunities and joint demand generation with sequencing instrument vendors.

Market Recognition Being named in The Sunday Times 100 Tech 2026 signals rapid growth and investor confidence, which can be leveraged to attract strategic partnerships, larger trial collaborations, and credibility when approaching prospective pharma and academic customers.

Epigenetics Focus Continuous advancement in epigenetic sequencing sample prep and single-base resolution multiomics positions biomodal as a specialized supplier for researchers needing precise methylation and hydroxymethylation data, appealing to labs transitioning to integrated omics workflows.

Growth Signals Revenue in the low to mid single-digit millions and a lean employee base suggest a scalable, nimble organization ripe for pilot projects, sponsored studies, or early adopter programs with biotech, contract research organizations, or pharmaceutical companies seeking innovative analytics.